fbpx

Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial

Add-on cannabidiol (CBD) reduced seizures associated with Dravet syndrome (DS) in two randomized, double-blind, placebo-controlled trials: GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or GWPCARE2, were enrolled in a long-term open-label extension trial, GWPCARE5 (NCT02224573). We present an interim analysis of the safety, efficacy, and patient-reported outcomes from GWPCARE5.

The post Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial appeared first on Society of Cannabis Clinicians.

Leave a Reply

%d bloggers like this: